I’m on a plane as I write this heading down to Florida to
visit the winning school from our Great Lemonade War contest (more on that in
another blog), but can’t ignore the great news that was announced last night in
the childhood cancer research world. If you haven’t already heard, early
results from a clinical trial found that a drug that was being used to treat
lung cancer in adults (crizotinib), was found to eradicate cancer in some kids
with a rare type of lymphoma (anaplastic large cell lymphoma – ALCL). That’s
right, eradicate – no trace of the
cancer can be found in 7 out of 8 kids who had ALCL and were enrolled in the
trial. Better yet, it was a simple pill that the kids took (versus getting
stuck as is the case with IV therapy), with minimal toxicity in spite of high
dosages, and within days of taking it – it helped reduce fevers, chills and pain
that some of the kids were previously experiencing. Awesome.
The research team, led by Yaël Mossé, MD from the Children’s
Hospital of Philly (CHOP), explains that crizotinib appears to be effective in
patients that test positive for the cancer causing gene, anaplastic lymphoma kinase (ALK).
Crizotinib specifically looks to disrupt this gene and voilà – if all goes as
planned, the cancer disappears. It’s all part of the personalized therapy
approach that so many researchers are exploring these days and for good reason.
Finding treatments that are effective in patients whose cancer has certain
characteristics helps to create customized treatment plans that not only work,
but also prevents kids from being subjected to other therapies or procedures
that they know won’t work.
Crizotinib also showed promise in kids with specific forms
of neuroblastoma that harbor the ALK
gene. Neuroblastoma was the type of cancer that Alex had and although the tests
for ALK were not available when she
was in treatment, you better believe we would have looked into it if it was.
One more neat piece of info – Alex's Lemonade Stand Foundation (ALSF) had a role in this
breakthrough! Although ALSF was not responsible for funding this particular
clinical trial, we did provide previous support to the research team that
allowed them to develop the trial. Dr. John Maris, one of the doctors who
treated Alex at CHOP states it a bit more eloquently than me:
"Funding through
ALSF was absolutely critical for the translation of our basic research findings
to a clinical trial. It is a highly complex process (and often difficult to
fund) to take a novel discovery and develop a safe and effective therapeutic
strategy. ALSF funding allowed us to be extremely facile in getting the work done
so that we could get a clinical trial open as soon as was humanly possible.
While the actual trial was funded by the National Cancer Institute through the
Children's Oncology Group, ALSF funding to CHOP to support core research
infrastructure also enhanced our ability to bring children to our center from
far and away for enrollment on the trial, and to receive the medication in a
safe and very efficient manner."
- John Maris, MD, Chief, Division of Oncology, and Director, Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia
- John Maris, MD, Chief, Division of Oncology, and Director, Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia
So what happens now? Well, doctors are working hard to get
crizotinib moved up to a front line treatment for kids with ALCL who present
with the ALK gene, and the
researchers are planning a larger scale trial for these patients as well as trials
to further investigate the drug’s efficacy in kids with neuroblastoma.
It’s news like this that energizes me and the work that we
do every day at ALSF – I’m sure the amazing researchers who work tirelessly to
make this their life’s work feel similarly. Progress is being made, we are
making a difference (thanks to your support) and kids’ lives are being saved.
Awesome.
-Jay Scott (Alex’s Dad)





